Union Health Minister Mansukh Mandaviya on Thursday said the government does not want to make haste about administering Covid vaccines to children and any decision in this regard will be taken based on expert opinion.
The government is currently procuring two other vaccines -- Covishield at Rs 205 per dose and Covaxin at Rs 215 per dose -- for the national COVID-19 immunisation programme.
A day after getting the emergency use authorisation (EUA) in India, country's leading multinational pharmaceutical company Zydus Cadila has said that the commercial rollout of its ZyCoV-D vaccine will start from mid-September. The pharma major informed about the future rollout plan in a virtual press conference held on Saturday.
The Drugs Controller General of India (DCGI) has granted authorization to Zydus Cadila's three-dose COVID-19 vaccine ZyCoV-D for emergency use in India.
The Centre said the vaccination is its top most priority and all efforts are being made to achieve " an objective of 100 percent vaccination in the shortest time possible keeping the available resources in mind and availability of vaccine doses into consideration".
NITI Aayog member (Health) Dr V K Paul said, "Moderna vaccine is under emergency use authorisation. The government is working actively with the manufacturers to see how to make this vaccine available in the country.
Zydus Cadila on Thursday said it has applied for emergency use authorisation (EUA) with the Drug Controller General of India (DCGI) for its COVID-19 vaccine ZyCoV-D.
New Delhi: The Drugs Controller General of India (DCGI) has approved conducting phase III trials of the country’s first DNA vaccine candidate against COVID-19 being developed by Zydus Cadila, the Department of Biotechnology said on Sunday. The vaccine candidate has been supported by the National Biopharma Mission (NBM) under the aegis of Biotechnology Industry Research […]
New Delhi: Drug firm Zydus Cadila on Thursday said it has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market. Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory […]
New Delhi: Drug firm Zydus Cadila on Wednesday announced that its plasmid DNA vaccine to prevent COVID-19 — ZyCoV-D — was found to be safe and well-tolerated in phase I clinical trial. The company will now commence phase II clinical trials from August 6. The company stated that the doses of the vaccine administered to […]
New Delhi: After Bharat Biotech’s Covaxin, another potential COVID-19 vaccine indigenously developed by Ahmedabad-based Zydus Cadila Healthcare Ltd got nod from the Drugs Controller General of India (DCGI) on Thursday for human clinical trials, government sources said. The approval process was fast-tracked following a recommendation by the subject expert committee on COVID-19, considering the emergency […]
Ahmedabad: Pharmaceuticals major Zydus Cadila on Saturday said that Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market an oral suspension of Oseltamivir powder, used for treatment and prevention of influenza. “Zydus’ Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from […]